Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 nov. 2023 07h00 HE | Source: Amydis, Inc.

Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Beta

Amydis announces Phase 2 clinical program for its novel retinal tracer, AMDX-2011P, to detect amyloid-beta in glaucoma patients.
22 sept. 2022 07h00 HE | Source: Amydis, Inc.

Amydis Announces Enrollment of First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Disease

SAN DIEGO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of diagnostic drug candidates targeting CNS biomarkers in the eye, today...
18 août 2022 07h00 HE | Source: Amydis, Inc.

Amydis Receives NIH Grant Award to Develop a Novel TDP-43 Retinal Tracer in Patients with ALS and FTD

SAN DIEGO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...